Glioma targeted therapy: insight into future of molecular approaches
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
gliomas occur among all ages, more often seen in adults, which males are more susceptible …
Targeted therapies for lung cancer patients with oncogenic driver molecular alterations
Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …
understanding of disease biology and the identification of oncogenic driver alterations has …
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
V Subbiah, RJ Kreitman, ZA Wainberg, A Gazzah… - Nature medicine, 2023 - nature.com
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
Kinase drug discovery 20 years after imatinib: progress and future directions
Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
PY Wen, A Stein, M van den Bent, J De Greve… - The lancet …, 2022 - thelancet.com
Background Effective treatments are needed to improve outcomes for high-grade glioma
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …
short time frame at an affordable cost. While this technology has been widely implemented …
Update 2020: management of non-small cell lung cancer
M Alexander, SY Kim, H Cheng - Lung, 2020 - Springer
The past decade has seen a revolution of new advances in the management of non-small
cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and …
cell lung cancer (NSCLC) with remarkable progresses in screening, diagnosis, and …
A comprehensive review on MAPK: a promising therapeutic target in cancer
The mitogen-activated protein kinase (MAPK) pathway is an important bridge in the switch
from extracellular signals to intracellular responses. Alterations of signaling cascades are …
from extracellular signals to intracellular responses. Alterations of signaling cascades are …